The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

MacroGenics has a strong cash position ... three molecules with our three core platforms, our FC engineered, our DART bispecific and our ADC platform are being pursued for treatments for various ...

MacroGenics' valuation has declined due to ... like the CD123-targeted DART molecule MGD024, the B7-H3 novel ADC MGC026 in phase 1 study, and MGC028, an ADAM9 ADC set to move into the clinic ...

MacroGenics is also investigating different mechanisms of action for mCRPC. The company is running a Phase II trial (NCT05848011) of lorigerlimab, a bispecific, tetravalent PD-1 × CTLA-4 DART ...

We will begin the MacroGenics Fourth Quarter and Full Year ... our bispecific tetravalent DART molecule designed to enable blockade of PD-1 and CTLA-4 with potentially enhanced CTLA-4 blockade ...